1. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

Target Protein Ligand-Linker Conjugate

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132943A

    Target Protein Ligand-Linker Conjugates Cancer
    BRD4 ligand-Linker Conjugate 1 TFA (compound 106-1) is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs .
    BRD4 ligand-Linker Conjugate 1 TFA
  • HY-131886

    E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide 4'-alkylC4-acid (linker16) is a E3 Ligase Ligand-Linker Conjugate. Pomalidomide 4'-alkylC4-acid can be used for conjugation to a target protein ligand .
    Pomalidomide 4'-alkylC4-acid
  • HY-157228

    PROTACs Others Cancer
    ACBI3 (compound 7) is a PROTAC targeting KRAS. ACBI3 is composed of PROTAC target protein ligand pan-KRAS degrader 1 (HY-162960) (red part), E3 ligase ligand E3 ligase Ligand 43 (HY-401613) (blue part) and PROTAC Linker 1-Bromo-4-(ethynyloxy)butane (HY-169992) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 143 (HY-169995) .
    ACBI3
  • HY-168693

    Target Protein Ligand-Linker Conjugates
    Target Protein Ligand-Linker Conjugates 2 is a conjugate of the Target Protein Ligand and Linker, consisting of Desmethyl-QCA276 (HY-44103) and the corresponding Linker. Target Protein Ligand-Linker Conjugates 2 can be used to synthesize PROTAC BD-9136 (HY-149878) .
    Target Protein Ligand-Linker Conjugates 2
  • HY-169490

    Target Protein Ligand-Linker Conjugates Cancer
    Target Protein Ligand-Linker Conjugates 3 is a conjugate generated by linking a target protein ligand (HY-44824) to a linker (HY-169489). Target Protein Ligand-Linker Conjugates 3 can be used in the synthesis of PROTACs (e.g. PROTAC SMARCA2 degrader-21 (HY-169272)) .
    Target Protein Ligand-Linker Conjugates 4
  • HY-169488

    Epigenetic Reader Domain Target Protein Ligand-Linker Conjugates Cancer
    SMARCA2 ligand-12-3-methylazetidin is a target protein ligand-linker conjugate that incorporates a ligand for SMARCA2 (HY-169487), and a PROTAC linker (HY-W052601), which recruit E3 ligases. SMARCA2 ligand-12-3-methylazetidin can be used to synthesize PROTAC SMARCA2 degrader-25 (HY-169276) .
    SMARCA2 ligand-12-3-methylazetidine
  • HY-153424

    Target Protein Ligand-Linker Conjugates Cancer
    PROTAC SMARCA2 degrader-1 (compound ex7) is a BRM2 (SMARCA2) degrader (DC50<0.1 μM). PROTAC SMARCA2 degrader-1 is also an E3 ubiquitin ligase binding linker useful in research of cancers. PROTAC SMARCA2 degrader-1 is a target protein ligand-linker conjugate .
    PROTAC SMARCA2 degrader-1
  • HY-132943

    Target Protein Ligand-Linker Conjugates Cancer
    BRD4 ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs.
    BRD4 ligand-Linker Conjugate 1
  • HY-169357

    E3 Ligase Ligand-Linker Conjugates Cancer
    Acepromazine-1-Piperazinepropanamine (compound 10) is a synthesized E3 ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugate) that incorporates a cereblon ligand and a linker. Acepromazine-1-Piperazinepropanamine can be connected to the target protein ligand to form a PROTAC molecule, TrimTAC1 (HY-169355) .
    Acepromazine-1-Piperazinepropanamine
  • HY-147225

    AUTACs Mitophagy Neurological Disease Metabolic Disease Cancer
    TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via mitophagy, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes .
    TSPO Ligand-Linker Conjugates 1
  • HY-160221

    PROTACs Androgen Receptor Cancer
    PROTAC AR Degrader-7 (compound 99) is a PROTAC targeting androgen receptor with an IC50 value of 3 nM. PROTAC AR Degrader-7 is composed of PROTAC target protein ligand AR ligand-32 (HY-170303) (red part), E3 ligase ligand E3 ligase Ligand 44 (HY-170304) (blue part) and PROTAC Linker N-Boc-piperazine (HY-30105) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 145 (HY-170305) .
    PROTAC AR Degrader-7
  • HY-142621

    PROTACs Btk Cancer
    BCPyr is a PROTAC-class BTK degrader (DC50 = 800 nM) . BCPyr consists of a PROTAC target protein ligand (red part) BTK ligand 11 (HY-168314), an E3 ubiquitin ligase ligand (blue part) E3 ligase Ligand 20 (HY-135997), and a PROTAC linker (black part) (5-(Bromomethyl)pyrazin-2-yl)methanol (HY-168315). E3 ubiquitin ligase+linker can form E3 Ligase Ligand-linker Conjugate 146 (HY-168316).
    BCPyr
  • HY-168274

    PROTACs Apoptosis Cancer
    PROTAC TRIB2 degrader-1 (Compound 5k) is an effective TRIB2 degrader that selectively induces TRIB2 degradation through the CRBN-dependent ubiquitin-proteasome pathway. PROTAC TRIB2 degrader-1 can inhibit cell proliferation and induce cell apoptosis, and can be used in cancer research. (Target protein ligand (Pink): HY-168275; linker (black): HY-168276; E3 Ligase Ligand-Linker Conjugates: HY-168277; E3 ligase (Blue): HY-W023573) .
    PROTAC TRIB2 degrader-1
  • HY-159651

    PROTACs 17β-HSD Cancer
    PTOTAC HSD17B13 degrader 1 (compound 1) is a PROTAC targeting 17β-HSD 13 (HSD17B13). PTOTAC HSD17B13 degrader 1 is composed of PROTAC target protein ligand HSD17B13 degrader 2 (HY-159662) (red part), PROTAC Linker tert-Butyl 5-bromoisoindoline-2-carboxylate (HY-W003696) (black part) and E3 ubiquitin ligase ligand E3 ligase Ligand 31 (HY-159660) (blue part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 114 (HY-159661) [1] .
    PTOTAC HSD17B13 degrader 1
  • HY-145925C

    PROTACs Epigenetic Reader Domain Cancer
    (S,R)-CFT8634 (compound 176) is a selective and orally active PROTAC-class BRD9 protein degrader. (S,R)-CFT8634 has the potential to study BRD9-mediated diseases, including but not limited to abnormal cell proliferation. (S,R)-CFT8634 consists of a target protein ligand (red part) BRD9 ligand-5 (HY-169988), an E3 ligase ligand (blue part) CRBN ligand-11 (HY-169989), and a PROTAC linker (black part) 1-(3,3-Difluoro-4-piperidinyl)piperazine (HY-169991). E3 ligase ligand and linker can form E3 Ligase Ligand-linker Conjugate 142 (HY-169990) .
    (S,R)-CFT8634

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: